** Shares of drug developer Marker Therapeutics MRKR.O fall 25.5% to $3 premarket
** MRKR announces $16.1 mln private placement
** Proceeds from this financing will support the clinical development of MT-601, a next-generation T cell-based therapy for relapsed lymphoma patients - MRKR
** Investors to pay a purchase price of $3.20/shr and warrants are exercisable for $4.03/shr
** As of last close, stock has fallen 26.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.